Danone is recalling more than 120 batches of infant formula in Austria due to possible contamination with toxin cereulide, Bloomberg News reported on Thursday. ...

Core Viewpoint - Abbott Laboratories has experienced significant stock underperformance compared to the broader market and key sector indices, raising concerns about its growth outlook and performance in critical segments [2][3][6]. Company Overview - Abbott Laboratories, with a market cap of $189.6 billion, operates globally in healthcare, focusing on pharmaceuticals, diagnostics, nutrition, and medical devices [1]. Stock Performance - Over the past 52 weeks, Abbott's stock has decreased by 15.1%, while the S&P 500 Index has gained 15.4% [2]. - Year-to-date, Abbott's stock has declined nearly 13%, contrasting with a 1.1% rise in the S&P 500 [2]. Segment Performance - In Q4 2025, Abbott reported revenue of $11.46 billion, missing Wall Street estimates, with adjusted EPS of $1.50 meeting expectations [6]. - Key segments showed weak performance: Nutrition sales fell by 8.9% reported (9.1% organic), and Diagnostics declined by 2.5% reported, attributed to lower volumes and reduced COVID-19 testing demand [6]. Growth Outlook - Abbott's organic sales growth outlook for 2026 is projected at 6.5% - 7.5%, which is below prior consensus expectations, contributing to investor concerns [6]. - For the fiscal year ending December 2026, analysts expect adjusted EPS to grow by 10.3% year-over-year to $5.68 [7]. Analyst Ratings - Among 28 analysts covering Abbott, the consensus rating is a "Strong Buy," with 20 "Strong Buy" ratings, two "Moderate Buys," and six "Holds" [7]. - Wells Fargo analyst lowered Abbott's price target to $122 while maintaining an "Overweight" rating, with a mean price target of $134.38 indicating a 23.3% premium to the current price [8].

Core Viewpoint - Danone is proactively recalling specific batches of infant formula products in response to evolving food safety guidance from local authorities, emphasizing its commitment to food safety and quality assurance [1][2]. Group 1: Company Actions - Danone is withdrawing a limited number of specific batches of infant formula products from targeted markets to comply with the latest food safety guidance [2]. - The company reassures parents and healthcare professionals about the safety and quality of its infant formula products [2]. Group 2: Company Overview - Danone is a leading global food and beverage company focused on health-oriented categories, including Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition [4]. - In 2024, Danone generated €27.4 billion in sales and operates in over 120 markets with a workforce of more than 90,000 employees [4]. - The company has a diverse portfolio of international and regional brands, including Actimel, Activia, and evian, and is committed to sustainability and health through its Renew strategy [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Perrigo securities between February 27, 2023, and November 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including issues related to underinvestment, necessary capital expenditures, and manufacturing deficiencies [5]. - As a result of these misstatements, Perrigo's financial results were overstated, leading to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from underinvestment and required substantial capital expenditures [4] - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results [4] - The misleading statements about Perrigo's business operations resulted in investor damages when the true details became public [4]

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The lawsuit asserts that the positive statements made by the defendants regarding Perrigo's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding Perrigo's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Perrigo Company plc regarding a class action lawsuit due to alleged misleading statements and operational deficiencies related to the company's infant formula business [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 27, 2023, to November 4, 2025, Perrigo issued materially false and misleading statements [3]. - Specific allegations include significant underinvestment in the infant formula business acquired from Nestlé, necessitating substantial capital and operational expenditures beyond stated cost estimates [3]. - The complaint also highlights significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [3]. Group 2: Class Action Details - Shareholders who purchased PRGO shares during the specified class period are encouraged to register for the class action, with a deadline of January 16, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflate stock prices [5].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2] - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2] - The complaint indicates that there were significant manufacturing deficiencies in the facility related to the infant formula business [2] - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were overstated [2] - The positive statements made by the defendants regarding Perrigo's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The lawsuit asserts that the positive statements made by Perrigo regarding its business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].